This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Cancer-associated fibroblast-derived SPP1 is a potential target for overcoming sorafenib and lenvatinib resistance in hepatocellular carcinoma. (October 2022)
Record Type:
Journal Article
Title:
Cancer-associated fibroblast-derived SPP1 is a potential target for overcoming sorafenib and lenvatinib resistance in hepatocellular carcinoma. (October 2022)
Main Title:
Cancer-associated fibroblast-derived SPP1 is a potential target for overcoming sorafenib and lenvatinib resistance in hepatocellular carcinoma